REFERENCES
1. Kox M, Bauer M, Bos LDJ, et al. The immunology of sepsis: translating new insights into clinical practice. Nat Rev Nephrol. 2026;22:30-49.
2. Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321:2003-17.
3. Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4:259-71.
4. Scicluna BP, van Vught LA, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5:816-26.
5. Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023;11:965-74.
6. Shankar-Hari M, Calandra T, Soares MP, et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respir Med. 2024;12:323-36.
7. Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, et al. The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nat Immunol. 2024;25:19-28.
8. Antcliffe DB, Burnham KL, Al-Beidh F, et al. Transcriptomic signatures in sepsis and a differential response to steroids. from the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199:980-6.
9. Yao L, Rey DA, Bulgarelli L, et al. Gene expression scoring of immune activity levels for precision use of hydrocortisone in vasodilatory shock. Shock. 2022;57:384-91.
10. Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693-704.
11. Sinha P, Furfaro D, Cummings MJ, et al. Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med. 2021;204:1274-85.
12. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. J Allergy Clin Immunol. 2021;147:72-80.e8.
13. Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:1137-46.
14. Riedemann NC, Guo RF, Hollmann TJ, et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. FASEB J. 2004;18:370-2.
15. Lindenkamp C, Plümers R, Osterhage MR, et al. The activation of JAK/STAT3 signaling and the complement system modulate inflammation in the primary human dermal fibroblasts of PXE patients. Biomedicines. 2023;11:2673.
16. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611-20.
17. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691-8.
18. Maddali MV, Churpek M, Pham T, et al. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022;10:367-77.
19. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195:331-8.
20. Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275-81.
21. Meyer NJ, Reilly JP, Anderson BJ, et al. Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med. 2018;46:21-8.
22. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752-60.
23. Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3:100817.
24. PRACTICAL, PANTHER, TRAITS, INCEPT, and REMAP-CAP investigators. The rise of adaptive platform trials in critical care. Am J Respir Crit Care Med. 2024;209:491-6.
25. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359-68.
26. Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140.
27. Bittle E, Arnold S, Hijano DR, Landman BM, Morton T, Hines M. Safety data for baricitinib use in children with severe SARS-CoV-2 infection. Hosp Pediatr. 2025;15:e203-8.
28. Albrecht EA, Ward PA. Complement-induced impairment of the innate immune system during sepsis. Curr Infect Dis Rep. 2005;7:349-54.
29. Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2002;110:101-8.
30. Bauer M, Weyland A, Marx G, et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis or septic shock-a randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS Study). Crit Care Explor. 2021;3:e0577.
31. Jin K, Ma Y, Manrique-Caballero CL, et al. Activation of AMP-activated protein kinase during sepsis/inflammation improves survival by preserving cellular metabolic fitness. FASEB J. 2020;34:7036-57.
32. Gómez H, Del Rio-Pertuz G, Priyanka P, et al. Association of metformin use during hospitalization and mortality in critically Ill adults with type 2 diabetes mellitus and sepsis. Crit Care Med. 2022;50:935-44.
33. Tan K, Simpson A, Huang S, Tang B, Mclean A, Nalos M. The association of premorbid metformin exposure with mortality and organ dysfunction in sepsis: a systematic review and meta-analysis. Crit Care Explor. 2019;1:e0009.
34. Saraiva IE, Hamahata N, Huang DT, et al. Metformin for sepsis-associated AKI: a protocol for the randomized clinical trial of the safety and feasibility of metformin as a treatment for sepsis-associated AKI (LiMiT AKI). BMJ Open. 2024;14:e081120.
35. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640-8.
36. Shibata M, Nanno K, Yoshimori D, et al. Myeloid-derived suppressor cells: cancer, autoimmune diseases, and more. Oncotarget. 2022;13:1273-85.
37. Kotsaki A, Pickkers P, Bauer M, et al. ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open. 2022;12:e067251.
38. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3:678-81.
39. Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186:838-45.
40. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230-51.
41. Delwarde B, Peronnet E, Venet F, et al. Low interleukin-7 receptor messenger RNA expression is independently associated with day 28 mortality in septic shock patients. Crit Care Med. 2018;46:1739-46.
42. Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3:98960.
43. Crausaz M, Monneret G, Conti F, et al. A novel virotherapy encoding human interleukin-7 improves ex vivo T lymphocyte functions in immunosuppressed patients with septic shock and critically ill COVID-19. Front Immunol. 2022;13:939899.
44. Liu M, Zhang X, Chen H, et al. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients. Scand J Immunol. 2017;85:66-72.
45. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88:233-40.
46. Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45:1360-71.
47. Liu LL, Skribek M, Harmenberg U, Gerling M. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature. J Immunother Cancer. 2023;11:e005841.
48. Leibundgut-Landmann S, Osorio F, Brown GD, Reis e Sousa C. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood. 2008;112:4971-80.
49. Willment JA, Marshall AS, Reid DM, et al. The human beta-glucan receptor is widely expressed and functionally equivalent to murine dectin-1 on primary cells. Eur J Immunol. 2005;35:1539-47.
50. der Meer JW, Joosten LA, Riksen N, Netea MG. Trained immunity: a smart way to enhance innate immune defence. Mol Immunol. 2015;68:40-4.
51. Viana JPM, Costa FF, Dias TG, et al. Glucans: a therapeutic alternative for sepsis treatment. J Immunol Res. 2024;2024:6876247.
52. Morris T, Stables M, Hobbs A, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 2009;183:2089-96.
53. Leijte GP, Kiers D, van der Heijden W, et al. Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: a randomized placebo-controlled study. Crit Care Med. 2019;47:508-16.
54. Trauer J, Muhi S, McBryde ES, et al. Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: an individual patient data meta-analysis using propensity matching. Crit Care Med. 2017;45:1871-9.
55. Eisen DP, Leder K, Woods RL, et al. Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial. Lancet Respir Med. 2021;9:186-95.
56. Johnstone J, Meade M, Lauzier F, et al. Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients: a randomized clinical trial. JAMA. 2021;326:1024-33.
57. Kim SG, Becattini S, Moody TU, et al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant enterococcus. Nature. 2019;572:665-9.
58. Kim SM, DeFazio JR, Hyoju SK, et al. Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nat Commun. 2020;11:2354.
59. Zhang L, Shi X, Qiu H, et al. Protein modification by short-chain fatty acid metabolites in sepsis: a comprehensive review. Front Immunol. 2023;14:1171834.
60. Jundi B, Lee DH, Jeon H, et al. Inflammation resolution circuits are uncoupled in acute sepsis and correlate with clinical severity. JCI Insight. 2021:6.
61. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol. 2016;16:51-67.
62. Rocheteau P, Chatre L, Briand D, et al. Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat Commun. 2015;6:10145.
63. Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science. 2017;356:1026-30.
64. Van Nynatten LR, Bokhary D, Wong MYS, et al. Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review. Crit Care. 2025;29:504.
65. Burnham KL, Davenport EE, Radhakrishnan J, et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med. 2017;196:328-39.
66. Kalil AC, Povoa P, Leone M. Subphenotypes and phenotypes to resolve sepsis heterogeneity: hype or hope? Intensive Care Med. 2025;51:582-4.
67. Scicluna BP, Cano-Gamez K, Burnham KL, et al. A consensus blood transcriptomic framework for sepsis. Nat Med. 2025;31:4119-30.
68. Burnham KL, Milind N, Lee W, et al. eQTLs identify regulatory networks and drivers of variation in the individual response to sepsis. Cell Genom. 2024;4:100587.
69. Liu X, Li J, Li R, et al. The relationship between serum alkaline phosphatase levels and sepsis: observational and Mendelian randomization studies. J Transl Genet Genom. 2025;9:182-93.
70. Alipanah-Lechner N, Neyton L, Sinha P, et al. Longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality. J Clin Invest. 2026:136.
72. Santacroce E, D’Angerio M, Ciobanu AL, et al. Advances and challenges in sepsis management: modern tools and future directions. Cells. 2024;13:439.
73. Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. Precision immunotherapy to improve sepsis outcomes: the ImmunoSep randomized clinical trial. JAMA. 2026;335:775-86.
